Kimberly Grigsby Sessoms, MD
Internal Medicine · Rose Hill, NCNPI 1396799334
Payments from drug & device makers
Across 183 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$886
- Sunovion Pharmaceuticals Inc.$625
- Lilly USA, LLC$434
- GSK$259
- AbbVie$237
- Avanir Pharmaceuticals, Inc.$226
- plus $930 from 24 others
What the payments were for
- Food & beverage$3,591100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $886 |
| Sunovion Pharmaceuticals Inc. | 57 | $625 |
| Lilly USA, LLC | 26 | $434 |
| GSK | 6 | $259 |
| AbbVie | 7 | $237 |
| Avanir Pharmaceuticals, Inc. | 10 | $226 |
| Bayer | 7 | $119 |
| Novartis | 5 | $89 |
| Sumitomo Pharma America, Inc. | 7 | $72 |
| Johnson & Johnson | 2 | $68 |
| Eisai Inc. | 4 | $68 |
| Nestle Healthcare Nutrition Inc. | 4 | $62 |
| UCB, Inc. | 3 | $54 |
| Merck | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Novo Nordisk | 2 | $30 |
| Pfizer | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Corium, LLC | 1 | $17 |
| Amgen | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,598 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 45 | $71,551 |
| JardianceEmpagliflozin | 63 | $69,166 |
| EliquisApixaban | 58 | $65,175 |
| OzempicSemaglutide | 49 | $59,916 |
| TrulicityDulaglutide | 49 | $58,562 |
| LinzessLinaclotide | 66 | $44,007 |
| FarxigaDapagliflozin Propanediol | 50 | $42,285 |
| XifaxanRifaximin | 11 | $35,361 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $27,824 |
| JanuviaSitagliptin Phosphate | 29 | $25,495 |
| EntrestoSacubitril/Valsartan | 28 | $23,152 |
| XareltoRivaroxaban | 48 | $19,186 |
| MounjaroTirzepatide | 15 | $15,539 |
| AptiomEslicarbazepine Acetate | 11 | $14,600 |
| TradjentaLinagliptin | 19 | $13,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $30 | $131,46894 claims |
| Boehringer IngelheimJardiance, Tradjenta | $23 | $83,08882 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $434 | $74,10264 claims |
| PfizerEliquis | $26 | $65,17558 claims |
| AstraZenecaFarxiga, Symbicort | $886 | $46,90962 claims |
| AbbVieLinzess | $237 | $44,00766 claims |
| MerckJanuvia, Janumet | $48 | $39,33640 claims |
| GSKTrelegy Ellipta | $259 | $27,82441 claims |
| NovartisEntresto | $89 | $23,15228 claims |
| Johnson & JohnsonXarelto | $68 | $19,18648 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $625 | $14,60011 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $72 | $10,91514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Rose Hill
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.